Shares of Pain Therapeutics have been lopped in half as Big Pharma partner Pfizer has put Pain's Remoxy, its lead drug candidate, under review. Durect has plunged more than 35%, as its extended-release tech is used in the product. 

In this video, health-care analyst David Williamson picks up the pieces for investors and takes a closer look at the abuse-resistant painkiller space while discussing the future of Pain Therapeutics.

David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.